GlobeNewswire

ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021

Share

GENEVA, Switzerland and BOSTON, MA – April 30, 2021 ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of five e-Posters on linzagolix in the treatment of uterine fibroids at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), which will take place virtually from April 30 to May 2, 2021.

The data presented further substantiate the best-in-class potential of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids addressing both key efficacy and safety parameters from the PRIMROSE Phase 3 program.

The posters being presented, along with lead authors and key conclusions are:

Poster #196:

Effects of the oral GnRH antagonist linzagolix on uterine and fibroid volume in two Phase 3 trials

Lead author: Jacques Donnez, MD, PhD; Professor, Société de Recherche pour l'Infertilité (SRI), Brussels and Catholic University of Louvain, Belgium

Key Conclusions: The 200 mg dose of linzagolix without hormonal add-back therapy (ABT) was the only dose to show consistent substantial and significant reductions in uterine and fibroid volumes. Linzagolix is the only GnRH antagonist with a high-dose non-ABT option with the potential for short-term use for reduction of uterine and fibroid volume.

Poster #231:

Impact of linzagolix on pain in patients with fibroid-related heavy menstrual bleeding: results of two Phase 3 trials

Lead author: Ayman Al-Hendy, MD, PhD; Professor, Department of Obstetrics and Gynecology, University of Chicago

Key Conclusions: Linzagolix 100 and 200 mg, with and without ABT, consistently improved pain in women with fibroid-associated HMB.  Pain reduction in the treatment groups was achieved after 12 weeks and was maintained up to 52 weeks.  By 12 weeks following termination of treatment, pain scores had increased but had not reached baseline levels.

Poster #2962:

Impact of linzagolix treatment on anemia in women with uterine fibroid related heavy menstrual bleeding:  results of two Phase 3 clinical trials

Lead author: William Catherino, MD, PhD; Professor, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences

Key Conclusions: High and low linzagolix doses with and without ABT improved hemoglobin and ferritin levels in anemic women with uterine fibroids.  In the 12-week follow-up period hemoglobin levels decreased but did not return to baseline levels.

Poster #194:

Safety of linzagolix in the treatment of women with uterine fibroids: Results from two Phase 3 clinical trials

Lead author: Hugh Taylor, MD; Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine

Key Conclusions: Overall treatment emergent adverse event (TEAE) rates at 24 weeks were similar to placebo for the linzagolix 100 mg and 200 mg with ABT regimens. Lumbar spine bone mineral density (BMD) z-scores indicated no change in risk categories. TEAE rates at Week 24 and BMD up to 52 weeks support the potential for long term use of linzagolix 100 mg and 200 mg with ABT.

Poster #1868:

Impact of linzagolix on events of depression and other mood disorders in women with uterine fibroids
Lead author: Robert Taylor, MD, PhD; Professor, Obstetrics and Gynecology, University at Buffalo

Key Conclusions: In the Phase 3 uterine fibroids trials of linzagolix, the incidence of depression and other mood disorder adverse events was low and revealed no consistent drug-related pattern.

All ePosters will be displayed on the ACOG Annual Meeting virtual platform in gallery view with search features by title, topic, and category. Each ePoster will have a dedicated page that will include a 5-minute prerecorded ePoster preview.

About Uterine Fibroids

Uterine fibroids are common benign tumors of the muscular tissue of the uterus. Uterine fibroids affect women of childbearing age and can vary in size from undetectable to large bulky masses. Few long-term medical treatments are available, and as a result, approximately 300,000 hysterectomies are performed for uterine fibroids every year in the US. The symptoms of uterine fibroids are wide-ranging and include heavy menstrual bleeding, anemia, pelvic pressure and bloating, urinary frequency and pain that can be extremely debilitating with a significant impact on quality of life. These symptoms can also have an impact on mental health, creating the additional burden of anxiety and distress.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

About Yselty® (Linzagolix)

Yselty® (linzagolix) is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world.

About Kissei

Kissei is a Japanese pharmaceutical company with approximately 70 years of history, specialized in the field of urology, kidney-dialysis and Unmet Medical Needs. Silodosin is a Kissei product for the treatment of the signs and symptoms of benign prostatic hyperplasia which is sold worldwide through its licensees. KLH-2109/OBE2109 is a new chemical entity discovered by Kissei R&D.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and other similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential therapeutic benefits and the clinical development of ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

New Management Appointments in Golar LNG Ltd.13.5.2021 15:05:36 CEST | Press release

The board of Golar LNG Limited ("Golar") is pleased to announce that they have appointed Mr. Karl Fredrik Staubo as the new Chief Executive Officer of the company in their board meeting on 13th May 2021. Mr. Staubo has since May 2020 been the Chief Executive Officer of Golar LNG Partners LP, recently successfully sold to New Fortress Energy. Since September 2020 Mr. Staubo has also been acting as Chief Financial Officer of Golar. Mr. Staubo has a broad shipping/energy background from Clarksons Platou Securities (2010-2018) and Magni Partners (2018-2020). He has a MA (Business Studies and Economics) from the University of Edinburgh. The board has in the same meeting also appointed Mr. Eduardo Maranhao to take over Mr. Staubo’s role as Chief Financial Officer of Golar. Mr. Maranhao has since 2015 been supporting Golar in different functions including as Chief Financial Officer of Golar Power/Hygo Energy Transition Limited until its recent sale to New Fortress Energy. Prior to joining the

Accumulus Synergy Appoint Francisco Nogueira as Chief Executive Officer13.5.2021 15:00:00 CEST | Press release

Accumulus is the first non-profit corporation designed to establish a relationship between technology, policy and collaboration between drug developers, NGOs, academic institutions and government agencies BURLINGAME, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Accumulus Synergy, a non-profit corporation intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, today announced the appointment of Francisco (Frank) Nogueira as the new chief executive officer (CEO). Mr. Nogueira was previously a vice president of Regulatory Affairs at Roche and served as interim CEO at Accumulus since the fall of 2020. Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities. The common-platform approach to data sharing aims to make the regulatory process more eff

Notification on convocation of the Joint Stock Company “Latvijas Gāze” Annual General Meeting of Shareholders13.5.2021 15:00:00 CEST | Press release

The Board of joint stock company “Latvijas Gāze”, registration number: 40003000642, legal address: Aristida Briana iela 6, Riga, LV-1001, Latvia (hereafter – the Company) calls up and announces that Annual General Meeting of Shareholders of the Company will take place on June 15, 2021 at 10.00 at the premises of the Company at Aristida Briana iela 6, Riga, LV-1001, Latvia using electronic means of communication. Agenda: Reports of the Board, the Council and the Audit Committee, and the certified auditor’s opinion.Approval of the Annual Report 2020.Distribution of the profit.Setting of remuneration to the members of the Council and the Audit Committee for the 2020 annual performance.Election of the auditor of the 2020 annual accounts and setting of remuneration to the auditor.Election of the Council and setting of remuneration to the Council. The record date for participation at the Annual General Meeting of Shareholders of the Company is June 7, 2021. Only those persons who are shareho

Vertex Acquires Taxamo to Expand Global Commerce and Compliance Solutions13.5.2021 13:30:00 CEST | Press release

European specialist in tax automation for e-commerce and marketplaces KING OF PRUSSIA, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of tax technology solutions, today announced it has acquired Taxamo, a cloud-based pioneer in tax and payment automation for global e-commerce and marketplaces. Taxamo, headquartered in Ireland, counts many of the leading, high-growth digital service providers among its global customers who rely on its unified platform of integrated capabilities to support indirect tax compliance, with a core focus on online sales, payments, and e-invoicing. “The fabric of today’s global commerce is more connected and complex than ever before,” said Vertex CEO David DeStefano. “Our mission is to enable every business to transact, comply and grow with confidence. We are incredibly excited to bring these new end-to-end solutions to our customers and partners around the world.” Taxamo’s cloud-based so

Results 2021 Annual General Meeting13.5.2021 08:30:00 CEST | Press release

PRESS RELEASE: Amsterdam – 13 May 2021.Intertrust N.V. (“Intertrust”) [Euronext: INTER], a global leader in providing tech-enabled corporate and fund solutions to clients operating and investing in international business, announces that in the Annual General Meeting of 12 May 2021 (2021AGM) the shareholders adopted all voting items on the agenda. At the 2021 AGM a total of 73.59% of the total issued share capital was represented. The results of the votes for each item on the agenda, will be published on our website https://www.intertrustgroup.com/investors/shareholder-information/annual-general-meeting-may-2021/ . Draft minutes of the 2021 AGM will be published no later than three months after the end of the meeting, after which shareholders should have the opportunity to react in the following three months. About Intertrust Intertrust has 4,000+ employees who are dedicated to providing world-leading, specialised administration services to clients in over 30 jurisdictions. This is ampl

Update on Kurdistan Payments13.5.2021 07:51:03 CEST | Press release

Oslo, 13 May 2021 – DNO ASA, the Norwegian oil and gas operator, today reported that Kurdistan’s Minister of Natural Resources has informed the international oil companies operating in the region of an intention to extend the payment period for arrears built up from non-payment of certain invoices in 2019 and 2020. As widely reported, last December the Prime Minister of Kurdistan announced a decision to pay the companies 50 percent of incremental revenue in any month in which Brent prices exceed USD 50 per barrel towards the arrears. The revised terms reduce the payment of the withheld amounts to 20 percent of incremental revenue above USD 50 per barrel. The Minister also advised that all international oil company invoices, including towards withheld amounts, will now be settled within 60 days of receipt. DNO is reviewing its position and will engage with Kurdistan to seek agreement regarding payment terms, interest on the arrears and revised lifting arrangements. – For further informa

Mandalay Resources Corporation Announces Financial Results for the First Quarter of 202113.5.2021 00:05:33 CEST | Press release

TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce its financial results for the quarter March 31, 2021. The Company’s condensed and consolidated interim financial results for the quarter ended March 31, 2021, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. First Quarter 2021 Highlights: Quarterly revenue of $52.6 million; highest since Q2 2016;Adjusted EBITDA of $26.1 million; third highest in Company’s history;Adjusted net income of $5.6 million ($0.06 or C$0.08 per share); andConsolidated net income of $25.5 million ($0.28 or C$0.35 per share). Dominic Duffy, President and CEO of Mandalay, commented: “Mandalay Resources is ple